Liko Ina, Lai Erika, Griffin Rachel J, Aquilante Christina L, Lee Yee Ming
Department of Pharmaceutical Sciences, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Pharmacopsychiatry. 2020 Nov;53(6):256-261. doi: 10.1055/a-1183-5029. Epub 2020 Jun 24.
There is growing interest to adopt pharmacogenetic (PGx) testing in psychiatric medicine, despite mixed views regarding its clinical utility. Nevertheless, providers are utilizing PGx testing among patients with mental health disorders. This study sought to assess genotyped patients' perspectives and experiences with psychiatric PGx testing.
Individual semi-structured interviews were conducted among patients with depression who had undergone psychiatric PGx testing. The audio-recorded interviews were transcribed and analyzed inductively and deductively for salient themes.
Twenty patients (100% Caucasian, 60% female, mean age 39±18 years) were interviewed. The majority of the PGx tests were provider-initiated for patients who failed multiple pharmacotherapies (50%) and/or had medication intolerances (45%). Patients' pre-testing expectations ranged from hopefulness to indifference to skepticism. Their post-testing experiences varied from optimism to disappointment, with the perceived value of the test influenced by the results and cost of the test.
Genotyped patients had mixed perspectives, expectations, and experiences with psychiatric PGx testing. Their perceived value of the test was influenced by the test outcomes and its cost.
尽管对于药物遗传学（PGx）检测在精神医学中的临床效用存在不同观点，但人们对其应用的兴趣与日俱增。尽管如此，医疗服务提供者仍在精神疾病患者中开展PGx检测。本研究旨在评估接受基因分型检测的患者对精神科PGx检测的看法和体验。
对接受过精神科PGx检测的抑郁症患者进行了个人半结构式访谈。对录音访谈进行转录，并采用归纳法和演绎法分析突出主题。
共访谈了20名患者（100%为白种人，60%为女性，平均年龄39±18岁）。大多数PGx检测是由医疗服务提供者为那些多种药物治疗失败（50%）和/或有药物不耐受（45%）的患者发起的。患者检测前的期望从充满希望到漠不关心再到怀疑不等。他们检测后的体验从乐观到失望各不相同，检测的感知价值受到检测结果和检测费用的影响。
接受基因分型检测的患者对精神科PGx检测有不同的看法、期望和体验。他们对检测的感知价值受到检测结果及其费用的影响。
